President Donald Trump disclosed the purchase of between $1 million and $5 million in Axon Enterprise stock on February 10, according to federal disclosures filed in May [1]. Two weeks after this transaction, on February 24, U.S. Immigration and Customs Enforcement (ICE) posted a notice seeking a five-year, $220 million contract for approximately 17,800 Tasers, unlimited cartridges, and training—enough to more than quadruple ICE's current Taser inventory of about 4,300 devices [1].
Although the ICE notice does not explicitly name Axon, procurement reviewers and policing experts told CNBC that the specifications in the notice appear to match only Axon products, specifically referencing an upgrade to the "T10" or "TASER 10" model, which features a 45-foot range and 10 individually targeted probes [1]. Axon currently supplies about 90% of U.S. Tasers, according to Brown Advisory, and already provides Tasers to the federal government [1]. The contract has not yet been awarded [1].
There is no evidence that Trump was involved in or had knowledge of the procurement process, nor that Axon was aware of his stock purchase [1]. The White House stated that Trump's assets are held in a trust managed by his children and that investments are managed by independent third-party firms, not by Trump or his family [1]. White House spokesperson Anna Kelly asserted, "There are no conflicts of interest," and described the scrutiny as a "tired narrative" pushed by Democrats [1].
Ethics experts cited by CNBC said the timing of the stock purchase and the ICE notice raises red flags, even though federal law exempts presidents from the criminal conflict-of-interest statute that applies to most executive branch officials [1]. Axon has increased its federal lobbying efforts, spending nearly $2.5 million on lobbying last year and hiring a former top Palantir employee as it expands its government business [1]. Trump's disclosures with the U.S. Office of Government Ethics, made public on May 14, show more than 3,700 transactions, with amounts listed as ranges rather than exact figures [1].
CONCLUSION
President Trump's significant Axon stock purchase shortly before ICE sought a major Taser contract has drawn scrutiny from ethics experts, though the White House denies any conflict of interest. The timing and scale of the potential ICE contract could have notable market implications for Axon, but the contract has not yet been awarded.